News from the healthcare data industry
Background – Colorectal liver oligometastases (CLO) represents a subset of metastatic colorectal cancer (mCRC) patients who may be eligible to undergo curative intent resection which can improve survival. However, given the...
September 12, 2022 06:30 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes...
Introduction For decades, the biopharmaceutical industry has used single sources of real-world data, including claims, electronic health records (EHRs), and cancer registries. Yet no one had amassed a large, harmonized...
Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance...
June 09, 2022 10:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed...
May 20, 2022 10:31 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Tempus N+, a program that aims to...
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial Collaborations will expedite identification of advanced...
March 21, 2022 09:58 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of EDGE, an innovative platform that allows pathologists...
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN...